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Abstract. Extracts of Cimicifuga racemosa are used
frequently for menopausal complaints. Cimicifuga is
well tolerated but can occasionally cause liver injury.
To assess hepatotoxicity of cimicifuga in more detail,
ethanolicC. racemosa extract was administered orally
to rats, and liver sections were analyzed by electron
microscopy. Tests for cytotoxicity, mitochondrial tox-
icity and apoptosis/necrosis were performed using
HepG2 cells. Mitochondrial toxicity was studied using
isolated rat liver mitochondria. Microvesicular stea-
tosis was found in rats treated with >500 mg/kg body
weight cimicifuga extract. In vitro, cytotoxicity was
apparent at concentrations 75 mg/mL, and mito-
chondrial b-oxidation was impaired at concentrations
10 mg/mL. The mitochondrial membrane potential
was decreased at concentrations 100 mg/mL, and
oxidative phosphorylation was impaired at concen-
trations 300 mg/mL. The mechanism of cell death
was predominantly apoptosis. C. racemosa exerts
toxicity in vivo and in vitro, eventually resulting in
apoptotic cell death. The results are compatible with
idiosyncratic hepatotoxicity as observed in patients
treated with cimicifuga extracts.
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Introduction
Hormone replacement therapy (HRT) has been
considered to be the standard treatment for meno-
pausal disturbances. The association of HRT with
breast and uterine cancer [1] and the desire of many
women for a “natural treatment” are themain reasons
why alternative therapies have become increasingly
popular; especially extracts of the plant Cimicifuga
racemosa are currently used for this indication.
C. racemosa, also called actaea racemosa or black
cohosh, is a member of the buttercup family (ranun-
culaceae) and originates from the Eastern part of the
United States and Canada. Traditionally, the rhizome
was used by North American Indians to treat joint
aches, myalgias, neuralgias and rheumatic disorders
but also for menopausal complaints and pain during
labour. Nowadays, ethanolic or isopropanolic extracts
of C. racemosa are most commonly used for the
symptomatic treatment of menopausal disorders and
premenstrual syndrome [2–5], although not all stud-
ies have shown a better effect than placebo [6].&dagger;&ensp;These authors contributed equally to this work.
*&ensp;Corresponding author.
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Data from clinical studies and spontaneous reporting
programs suggest that adverse events associated with
C. racemosa are rare, generally mild and reversible.
Gastrointestinal upset and rashes were the most
common adverse events reported [7, 8]. In mostly
uncontrolled clinical trials and post-marketing studies
including more than 2800 patients, adverse events had
an incidence of 5.4%. Of the reported adverse events,
97% were minor or mild, none of them resulting in
discontinuation of the therapy. When higher doses
than those recommended are used, however, C. race-
mosa can cause dizziness, headaches, nausea and
vomiting [8]. In their review, which includes all post-
marketing programs of cimicifuga extracts, Huntley et
al. also described patients with adverse hepatic events
[7]: they reported one case with hepatic failure, three
cases with hepatitis and three cases with increased
liver enzymes. In addition, several case reports have
been published about patients developing acute
hepatitis [9, 10] or fulminant liver failure [11–13]
while being treated with cimicifuga extracts. The
European Medicines Agency (EMEA) recently as-
sessed the case reports of hepatotoxicity associated
with ingestion of C. racemosa root extracts (EMEA/
HMPC/88766/2006) and concluded that the cases
reported in the literature as well as the pharmacovi-
gilance reports are mostly poorly documented and
that these adverse events should be interpreted with
caution. Systematic investigation of the present and
possible future cases by the marketing authorization
holders and pharmacovigilance units is appreciated by
the EMEA.
Since an association of hepatotoxicity with cimicifuga
appears to be possible, we decided to investigate the
potential for hepatotoxicity of cimicifuga extracts in
experimental animals in vivo, hepatocyte cultures and
isolated liver mitochondria.
Materials and methods
Chemicals. The cimicifuga extract was obtained from
Max Zeller Sçhne AG (Romanshorn, Switzerland,
batch number V2009). The extraction solvent was
60% ethanol (v :v) with a ratio of native herbal drug
to drug preparation of 4.5–8.5 : 1 (w :w), depending on
the content of triterpene glycosides (6%). Solutions
of the extract were made by dissolving it in DMSO.
Caffeic acid and ferulic acid were purchased from
Fluka (Buchs, Switzerland), and cimiracemoside A
was from ChromaDex (Santa Ana, CA, USA). JC-1
and propidium iodide were from Molecular Probes
(Eugene, OR, USA), and Z-Val-Ala-Asp-fluorome-
thylketone (zVAD-fmk) and Z-Phe-Ala-fluorome-
thylketone (zFA-fmk) were from Enzyme Systems
Products (Livermore, CA, USA). Alexa Fluor 633-
labelled annexin V was a generous gift of Dr. Felix
Bachmann, Aponetics Ltd. (Witterswil, Switzerland).
[1– 14C] palmitic acid was obtained from Amersham
Pharmacia Biotech (Dbendorf, Switzerland). The
scintillation cocktail was from Perkin Elmer (Boston,
MA, USA). The Cy3TM-conjugated anti-sheep IgG
was purchased from Jackson Laboratories (West
Grove, PA, USA). All other chemicals were from
Sigma (Buchs, Switzerland) and of the highest quality
available when not otherwise stated.
In vivo hepatotoxicity of cimicifuga extract.Groups of
five female Wistar rats were fed daily with doses of 1,
10, 100, 300 or 1000 mg/kg body weight C. racemosa
extract. The extract was administered as a suspension
in a solution of Arabic gum in water by means of
esophageal gavage over a period of 21 days. After
anaesthesia and decapitation, the livers of the animals
were perfused for fixation, and tissue blocks were
excised and prepared for electron microscopy as
described previously in detail [14]. The study protocol
had been accepted by the Animal Ethics Committee
of the Canton of Basel.
Cell culture. The human hepatocarcinoma cell line
HepG2 was kindly provided by Dr. Dietrich von
Schweinitz (Department of Pediatric Surgery, Child-
rens Hospital, University of Basel). The cell line was
grown in RPMI 1640 medium supplemented with
GlutaMAXTM-I, 25 mM Hepes, 10% (v :v) heat-
inactivated fetal bovine serum and 100 U/mL pen-
icillin/streptomycin (all from Gibco, Paisley, UK).
Culture conditions were 5% CO2 and 95% air atmos-
phere at 378C. Experiments were performed when the
cells had reached a confluence of about 80%.
Cytotoxicity tests. To examine cell viability and
reductive activity, the MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] assay was
performed in HepG2 as described originally by
Mosmann [15] but including an additional washing
step [16]. In addition, the sulforhodamine B (SRB)
test was performed according to the protocol of
Skehan [17] and the lactate dehydrogenase (LDH)
assay according to Vassault [18].
Isolation of rat liver mitochondria. Male Sprague
Dawley rats (Charles River, Les Onins, France) were
anaesthetized with carbon dioxide and killed by
decapitation. Liver mitochondria were isolated by
differential centrifugation according to the method of
Hoppel et al. [19]. The mitochondrial protein content
was determined using the biuret method with bovine
serum albumin as a standard [20].
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In vitro mitochondrial b-oxidation. Beta-oxidation
with freshly isolated liver mitochondria was assessed
as the formation of 14C-acid-soluble b-oxidation
products from [1– 14C] palmitic acid in the presence
of the cimicifuga extracts. Experiments were per-
formed as described initially by Freneaux et al. [21]
with themodifications described by Spaniol et al. [22].
Cimicifuga extract was added to the incubation
mixture just before starting the experiment.
Oxygen consumption. Polarographic monitoring of
oxygen consumption in rat liver mitochondria was
carried out in a 1-mL chamber equipped with a Clark-
type oxygen electrode (Yellow Springs Instruments,
Yellow Springs, OH, USA) at 308C as described
previously [23]. Subsequent experiments with the F1
F0-ATPase inhibitor oligomycin (5 mg/mL) were per-
formed to check for uncoupling of oxidative phos-
phorylation [24]. Cimicifuga extract was added to the
incubation mixture just before starting the experiment.
Mitochondrial membrane potential. To determine the
mitochondrial membrane potential, the dye JC-1
(5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethyl-benzimidazo-
lylcarbocyanine iodide) was used according to the
protocol of Molecular Probes. Cells were incubated
with different concentrations of cimicifuga extract for
24 h. After the addition of JC-1 and 10 min of
incubation, cell fluorescence was determined by flow
cytometry (FACSCalibur, Becton Dickinson, Frank-
lin Lakes, NJ, USA) [25].
Determination of intracellular GSH and GSSG con-
tent. In order to assess the redox status of the treated
HepG2 cells and possible formation of reactive
metabolites, determination of GSH (glutathione)
and GSSG (oxidized glutathione) was performed
using the enzymatic recycling assay of Tietze [26],
with themodifications described byGriffith et al. [27].
Apoptosis/necrosis. Discrimination between apopto-
sis and necrosis was done with annexin V/propidium
iodide staining. HepG2 cells were incubated for 24 h
with the extract. After trypsinization and centrifuga-
tion, cells were resuspended in RPMI medium (ad-
justed to 2.5 mM calcium), stained with Alexa Fluor
633-labelled annexin V and propidium iodide (final
concentration 1 mg/mL) and analyzed by FACS
(FACSCalibur, Becton Dickinson) [24].
ATP determination. The ATP content of HepG2 cells
treated with cimicifuga extract was determined with
the luciferin/luciferase method using the ATP bio-
luminescence assay kit from Sigma as described
previously [24].
Hoechst staining. HepG2 cells were incubated with
cimicifuga extract for 24 h, stained with 0.1 mM
Hoechst 33342 dye and visualized with an inverted
fluorescent microscope (Olympus IX50, Hamburg,
Germany).
Cytochrome c staining. HepG2 cells (105 cells) were
seeded into an 8-well chamber slide (Nunc Labtek,
Naperville, IL, USA) and cultured for 2 days. Sub-
sequently, cells were incubated for 24 h with cimici-
fuga extracts as described in the Results. The cells
were fixed in 4% paraformaldehyde and analyzed for
cytochrome c as described previously [24].
Statistical methods. Data represent the mean  SEM
of at least three replicates. Statistical analysis of
differences between control incubations and incuba-
tions with cimicifuga extract was performed using
analysis of variance (ANOVA) and Dunnetts multi-
ple comparison test as a posthoc test to localize
differences obtained byANOVA.Ap value<0.05was
considered to be statistically significant.
Results
Our aims were to find out whether cimicifuga is
hepatotoxic in vivo in rats and, if in vivo hepatotox-
icity could be demonstrated, to find out its mecha-
nisms by in vitro investigations. There were no differ-
ences in food consumption and body weight increase
between the rats treated with cimifuga extract and the
respective control rats (data not shown). Rats treated
with vehicle only showed no signs of hepatic toxicity.
Rats treated with 10 mg per kg body weight showed a
slight increase in the volume of hepatocellular mito-
chondria (mitochondrial swelling) and an enlarge-
ment of bile canaliculi (data not shown). Rats fed with
100 or 300 mg/kg body weight showed more marked
mitochondrial swelling and alterations in mitochon-
drial morphology such as vacuoles in the matrix
(Fig. 1a). Rats treated with 1000 mg/kg body weight
developed microvesicular steatosis of the hepatocytes
(see Fig. 1b), glycogen depletion and fragmentation of
the rough endoplasmic reticulum.
Since microvesicular steatosis usually reflects mito-
chondrial damage and can be associated with cytotox-
icity [28, 29], the MTT test was carried out on HepG2
cells. As shown in Fig. 2, cimicifuga extract displayed a
concentration-dependent toxicity starting at 75 mg/
mL. Cytotoxicity of cimicifuga could be confirmed
using the LDH and sulforhodamine B tests (data not
shown). In contrast, specific components of the
cimicifuga extract, namely caffeic acid, ferulic acid
or cimiracemoside A, which were investigated at
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concentrations calculated to be equivalent to those in
the extract, were not cytotoxic (data not shown).
Microvesicular steatosis and a signal in the MTT test
were compatible with mitochondrial toxicity associ-
ated with cimicifuga extract. The mitochondrial
membrane potential was therefore determined in
HepG2 cells treatedwith cimicifuga extract using JC-1
as a marker [25]. These experiments revealed a dose-
dependent decrease in the membrane potential,
starting at a concentration of 100 mg/mL (see Fig. 3).
In order to determine the reasons for the observed
decrease in the mitochondrial membrane potential,
specific mitochondrial functions were studied using
freshly isolated rat liver mitochondria. The investiga-
tion of palmitate metabolism revealed that C. race-
mosa inhibited mitochondrial b-oxidation in a dose-
dependent fashion, starting at a concentration of
10 mg/mL (Fig. 4). At a concentration of 500 mg/mL,
the residual activity was only 8.5%.
Oxidative phosphorylation is another important met-
abolic process in mitochondria that is sensitive to
toxicants [30]. As shown in Table 1, state 3 oxidation
rates in the presence of L-glutamate were decreased
by 20%starting at a concentration of 300 mg/mLof the
extract, whereas state 4 oxidation rates were increased
by 53% or 132% at 300 or 500 mg/mL, respectively. In
contrast, cimiracemoside A affected neither state 3
nor state 4 oxidation rates (Table 1). In order to prove
uncoupling of oxidative phosphorylation (as suggest-
ed by the increased state 4 oxidation rates), state 4u
was induced by the addition of oligomycin, an inhibitor
of F1F0-ATPase. As shown in Fig. 5, 500 mg/mL cimici-
fuga extract led to a significant increase in state 4u
oxygen consumption, similar to the known uncoupler
dinitrophenol. In contrast, such an increase could not
be shown in the presence of cimiracemoside A.
Since impairment of mitochondrial function (e.g.
impaired activity of the respiratory chain) can be
associated with increased production of ROS [24, 25],
the redox status of HepG2 cells was assessed by
determining their glutathione content; neither raised
GSSG levels nor an increased GSSG/GSH ratio was
Figure 1. Electron micrograph of a liver from a rat treated with
300 mg/kg body weight (a) shows swollen mitochondria (marked
with stars) beside mitochondria with a normal size. The bright,
swollen mitochondrion (black star) has a loose matrix and is
probably non-functioning. A semi-thin section of a liver from a rat
treated with 1000 mg cimicifuga extract/kg body weight for 21 days
(b) shows hepatocytes with intracellular accumulation of small
lipid droplets, which are located in the cytoplasm and do not
displace the nuclei, typical for microvesicular steatosis.
Figure 2. Reductive capacity and
integrity of HepG2 cells investigat-
ed using the MTT test after incu-
bation with cimicifuga extracts for
24 h. The concentration of DMSO
was 0.1% in all incubations. In
intact cells, MTT is metabolically
converted to its blue formazan
form, whose absorption can be
measured at 550 nm (presented
here). Cytotoxicity is detectable
beginning at a concentration of
75 mg/mL cimicifuga extract. Re-
sults areexpressedasmean SEM
of ten determinations (*p< 0.05,
**p< 0.01 vs. control values).
Cell.Mol. Life Sci. Vol. 64, 2007 Research Article 2851
detectable in the presence of cimicifuga extract (up to
500 mg/mL), suggesting that ROS do not play a
significant role in cimicifuga hepatotoxicity (data not
shown).
As it is well established that mitochondrial damage
can be associated with apoptosis and/or necrosis [24,
25, 31], we assessed these possibilities using annexinV
and propidium iodide staining of HepG2 cells. As
shown in Fig. 6, cimicifuga extract induced a concen-
tration-dependent increase in early apoptotic and, to a
smaller extent, also late apoptotic/necrotic cells start-
ing at a concentration of 300 mg/mL. The specificity of
Figure 3. Mitochondrial mem-
brane potential in HepG2 cells
incubated with cimicifuga ex-
tract. Cells were incubated with
cimicifuga extract for 24 h. After
this incubation, JC-1 was added
(final concentration 7.5 mM), and
cell fluorescence was analyzed
using a cell sorter after an incu-
bation of 10 min [25]. The con-
centration ofDMSOwas 0.1% in
all incubations. Themitochondri-
al membrane potential started to
drop at a concentrationof 100 mg/
mL cimicifuga extract, corre-
sponding well with the MTT test
shown in Fig. 2. Results are ex-
pressed as the percentage of the
membrane potential compared
to control values, which was set
at 100%. Results are presented
as mean  SEM of three deter-
minations (*p < 0.05 vs. control
values).
Figure 4. Activity of the b-oxi-
dation pathway of isolated rat
liver mitochondria in the pres-
ence of cimicifuga extract. b-
oxidation, measured as the for-
mation of ketone bodies using
[1– 14C] palmitic acid as a sub-
strate, was determined using
freshly isolatedmitochondria. Ci-
micifuga extract was added to the
incubation mixture just before
starting the experiment. The con-
centration of DMSOwas 0.1% in
all incubations. Cimicifuga ex-
tract showed dose-dependent
toxicity starting at a concentra-
tion of 10 mg/mL. Results are
expressed as mean  SEM of
three determinations (*p < 0.05,
**p < 0.01 vs. control values).
2852 S. Lde et al. Hepatic effects of Cimicifuga racemosa
this mechanism was shown by adding the pan-caspase
inhibitor zVAD-fmk to the incubations, which was
able to prevent early (but not late) apoptosis signifi-
cantly. In contrast, the cysteine protease inhibitor
zFA-fmk, which does not affect caspases, had no effect
on apoptosis associated with cimicifuga extract. To
further confirm these results, Hoechst 33342 staining
was performed, which confirmed that treatment with
cimicifuga extract is associated with apoptosis of
HepG2 cells (data not shown).
In order to better discriminate between late apoptosis
and necrosis in the annexin V/propidium iodide
staining, the ATP content of HepG2 cells treated
with cimicifuga extract was determined. For the
occurrence of apoptosis, normal levels of ATP are
necessary, whereas low levels of ATP are indicative of
necrosis [32]. The ATP levels of the cells treated with
cimicifuga extract were not decreased compared to
untreated control cells, indicating the occurrence of
apoptosis and not necrosis (data not shown).
To investigate the possible contribution of mitochon-
dria in the development of apoptosis associated with
cimicifuga extract, mitochondrial leakage of cyto-
chrome c was investigated using an immunohistolog-
ical method [24, 25]. As shown in Fig. 7, cimicifuga
extract was associated with mitochondrial leakage of
cytochrome c into the cytoplasm of HepG2 cells
starting at a concentration of 200 mg/mL.
Table 1. Effect ofCimicifuga racemosaonmitochondrial oxidative
metabolism.
Incubation State 3 State 4
Control (0.1% DMSO) 70  4 9.3  0.4
Cimicifuga 10 mg/mL 75  7 9.6  0.5
Cimicifuga 50 mg/mL 70  7 10.3  0.9
Cimicifuga 100 mg/mL 61  6 8.6  0.7
Cimicifuga 200 mg/mL 61  3 11.4  0.5
Cimicifuga 300 mg/mL 56  4* 14.2  1.1*
Cimicifuga 500 mg/mL 56  3* 21.6  0.9*
Cimiracemoside A 0.05 mg/mL 73  7 9.3  1.3
Cimiracemoside A 0.5 mg/mL 86  20 9.6  1.6
Cimiracemoside A 5.0 mg/mL 73  15 8.2  1.3
L-Glutamate (20 mmol/L) was used as a substrate. Oxygen con-
sumption by freshly isolated rat livermitochondria was determined
using an oxygen electrode as described in the Materials and
methods. Cimicifuga extract was added to the incubation mixture
just before starting the experiment. The concentration of DMSO
was 0.1% in all incubations. Oxygen consumption is expressed as
natoms/min/mgmitochondrial protein.Data are presentedasmean
 SEM (n  4 individual observations; *p < 0.05 vs. control in-
cubations).
Figure 5. Oxygen consumption
in the presence of L-glutamate
(20 mmol/L, as a substrate) and
the F1F0-ATPase inhibitor oligo-
mycin (5 mg/mL). In the presence
of oligomycin, any increase in
oxygen consumption has to be
due to uncoupling of the respira-
tory chain, since ADP cannot be
phosphorylated to ATP. Cimici-
fuga extract was added to the
incubation mixture just before
starting the experiment. The con-
centration ofDMSOwas 0.1% in
all incubations. Cimicifuga ex-
tract started to uncouple oxida-
tive phosphorylation at a concen-
tration of 300 mg/mL, which is in
accordance with the state 4 oxi-
dation rates shown in Table 1. In
contrast, cimiracemoside A did
not act as an uncoupler. Dinitro-
phenol was used as a positive
control. Results are expressed as
mean  SEM of four determina-
tions (**p < 0.01 vs. control in-
cubations).
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Discussion
The main finding in vivo and in vitro was hepatic
mitochondrial toxicity, as evidenced bymicrovesicular
steatosis and inhibition of b-oxidation and the respi-
ratory chain, eventually leading to apoptotic cell
death. While inhibition of the respiratory chain and
uncoupling of oxidative phosphorylation could be
demonstrated starting at concentrations of 300 mg/
mL, inhibition of b-oxidation appeared at much lower
concentrations (starting at 10 mg/mL) and was quite
strong, suggesting that it represents the most relevant
mechanism of mitochondrial toxicity associated with
cimicifuga. Severe inhibition of hepatic mitochondrial
b-oxidation is associatedwith cellular accumulation of
long-chain fatty acids, e.g.palmitate,which, depending
on the localization of the defect, may still be activated
to the respective acyl-coenzymes A (CoAs) and form
triglycerides [33]. Triglycerides can be stored in
hepatocytes, possibly leading to liver steatosis, or can
be exported from hepatocytes as very low-density
lipoprotein (VLDL) particles [28, 33, 34]. The micro-
vesicular type of steatosis is thought to result from
accumulation of triglycerides, acyl-CoAs and long-
chain fatty acids due to inhibited b-oxidation [28, 34],
which is different from the macrovesicular type of
liver steatosis, where accumulation of triglycerides is
predominant.
Our studies suggest that inhibition of b-oxidation is
the initial hepatotoxic event caused by cimicifuga
extract, which eventually may result in apoptosis of
the hepatocytes. Since long-chain acyl-CoAs accumu-
late in the cytoplasm of hepatocytes when b-oxidation
is impaired [33], these fatty acid metabolites may be
associated with hepatocellular toxicity. Saturated
long-chain fatty acids such as palmitate have indeed
been shown to be associated with apoptosis both in
vivo [35] and in cell cultures including hepatocytes
[35–37]. Palmitoyl-CoA can induce mitochondrial
membrane permeability transition, release of cyto-
chrome c into the cytoplasm and apoptosis via
caspase-dependent pathways [38]. Many of our find-
ings, e.g. prevention of apoptosis by the pan-caspase
inhibitor zVAD and release of cytochrome c into the
cytoplasm HepG2 cells, are in agreement with this
mechanism.
Palmitate and/or palmitoyl-CoA can induce apoptosis
by different mechanisms. One possibility is increased
Figure 6. Early apoptosis (black, grey or shaded columns) and late apoptotis/necrosis (white columns) of HepG2 cells incubated with
different concentrations of cimicifuga extract and other test compounds. After incubation with the test compounds for 24 h, cells were
stainedwith annexinVand propidium iodide, and cell fluorescencewas analyzed using a cell sorter. The concentration ofDMSOwas 0.1%
in all incubations. Thismethod allows allocation of cells into the categories living cells, early apoptotic cells and late apoptotic/necrotic cells
[24].While control incubations contain only a small percentage of apoptotic or necrotic cells, incubationwith FAS ligand (positive control)
is associated with a significant increase in early apoptotic cells. This increase can be inhibited by co-incubation with zVAD, a pan-caspase
inhibitor. In contrast, the increase is not inhibited in the presence of zFA, a cysteine protease inhibitor without activity against caspases.
Cimicifuga extract is associated with early apoptosis (and to smaller extent also late apoptosis/necrosis) starting at a concentration of
300 mg/mL. Early apoptosis but not late apoptosis/necrosis could at least partially be prevented by the addition of zVAD but not zFA.
Results are expressed as mean SEM of three determinations (*p < 0.05, **p < 0.01 vs. the respective control incubations, +p < 0.05 vs.
the respective incubation containing no zVAD).
2854 S. Lde et al. Hepatic effects of Cimicifuga racemosa
formation of ceramide, which can induce mitochon-
drial membrane permeability transition [39] and is
important for apoptosis associated with TNF-a [40].
However, while the addition of palmitate was asso-
ciated with increased ceramide formation by cultured
hepatocytes, inhibition of ceramide synthesis did not
prevent apoptosis [37]. In addition, in rat neonatal
cardiomyocytes, decreased cardiolipin synthesis was
found in the presence of palmitate, which was
associated with increased release of cytochrome c
into the cytoplasm and initiation of apoptosis [41].
The main constituents of C. racemosa are triterpene
glycosides (e.g. actein, deoxyactein, cimifugoside,
cimiracemosides), aromatic acids and their deriva-
tives (e.g. ferulic acid, isoferulic acid, caffeic acid,
fukinolic acid, cinnamic acid esters and cimicifugic
acidA andB), flavonoids, volatile oils and tannins [42,
43]. The components responsible for the pharmaco-
logical activity have so far not been identified.
Regarding toxicity, Hostanska et al. investigated
triterpene glycosides and cinnamic acid esters for
their ability to induce apoptosis [44–46]. Both types
of substances were found to be associated with
caspase-dependent apoptosis in breast cancer [44,
45] and prostate cancer cell lines [46]. In another
investigation, the formation of quinine metabolites
(possibly generated from phenolic acids and deriva-
tives) has been proposed to be the cause of cimicifuga
toxicity [47]. On the other hand, in the in vitro study
performed by Hostanska et al. [44], addition of
microsomes to the incubations did not increase the
toxicity of cimicifuga constituents, arguing against the
formation of toxic metabolites. In our investigations,
we did not focus on the formation of metabolites,
although it is possible that some of the constituents
mayhave beenmetabolized byHepG2 cells during the
24 h incubation period. In order to find out precisely
which component of cimicifuga extract is hepatotoxic,
the most important components of cimicifuga extract
would have to be studied individually, butmost of them
are not commercially available.
To assess whether the toxic concentrations are in the
range of the blood concentrations reached after
ingestion of cimicifuga tablets, a rough estimate can
be made. Assuming that a preparation containing 5–
10 mg ethanolic extract is ingested and that the entire
extract is absorbed rapidly, a maximal plasma con-
centration in the range of 1.5–3 mg/mL could be
reached (assuming rapid intravascular distribution, a
plasma volume of 3.5 L and absence of significant
metabolism). This value almost approaches the con-
centrations found to inhibit b-oxidation in our in vitro
experiments (lowest inhibitory concentration 10 mg/
mL) but is 30 or 150 times lower than the lowest
concentration associated with cytotoxicity (Fig. 2) or
apoptosis (Fig. 6), respectively. On the other hand, in
Figure 7. Immunohistological staining of cytochrome c in HepG2 cells. Cells (n = 105) were incubated for 24 h with cimicifuga extracts.
The concentration of DMSO was 0.1% in all incubations. After treatment, the cells were fixed with 4% paraformaldehyde, washed and
incubated with anti-cytochrome c antibody and, after washing, with Cy3-conjugated anti-sheep IgG [24]. In control incubations (1%
DMSO), cytochrome c has a granular structure and does not cover the nucleus (arrows). In the presence of 10 mg/mL cimicifuga extract, the
pattern of cytochrome c does not change. In the presence of 200 mg/mL cimicifuga extract, the granular appearance of cytochrome c
changes to a more diffuse appearance, and cytochrome c starts to cover the nucleus (arrows); some cells are completely covered by
cytochrome c (arrows). In the presenceof 500 mg/mL cimicifuga extract, these changes are evenmore accentuated (arrows). In comparison,
treatment with 100 mmol/L amiodarone (positive control) is associated with complete staining of the cells by cytochrome c, but cells detach
from the plate, indicating loss of cell integrity. Incubation with the second antibody only was used as a negative control.
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rats in vivo, microvesicular steatosis of the liver was
observed at 1000 mg extract per kg body weight.
Assuming a rapid and complete absorption of the
extract and a plasma volume of 15 mL, the maximal
plasma concentration would be in the range of 20 mg/
mL, a concentration too high to be tested in vitro due
to solubility problems. These considerations suggest
that toxic concentrations can most probably not be
reached in humans treated with the recommended
doses. This is in agreement with the toxicity profile of
the drug, showing hepatic adverse events only in a
small fraction of patients, possibly with as-yet-un-
known risk factors [7, 8].
In conclusion, ethanolic cimicifuga extract is associ-
ated with hepatic mitochondrial toxicity both in vivo
in rats and in vitro using cell cultures and isolated rat
liver mitochondria. This toxicity is not clinically
relevant for most patients but may become important
in patients with underlying risk factors.
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